Evidence map›Paper›PMID 41717934›Full record

Trial reportJournal of the American Heart Association2026

Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial.

Iyas Daghlas, Michelle R Caunca, Anthony S Kim

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00991029 (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00991029 phase3terminatednot on this map

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2018Enrolled4,881ConditionsIschemic Attack, TransientArmsClopidogrel, placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Iyas DaghlasUCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA.ORCID 0000-0001-6924-0641
Michelle R CauncaUCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA.ORCID 0009-0001-6641-1086
Anthony S KimUCSF Weill Institute for Neurosciences, Department of Neurology University of California San Francisco San Francisco CA.ORCID 0000-0002-8095-6517

Funding

NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25)UE5NS070680 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Scott Andrew Josephson · 2024 to 2026
$2.6M
NINDS NIH HHS UE5 NS070680
6 · The paper itself

Abstract

backgroundThe ABCD

methodsWe conducted a post hoc analysis of high-risk patients with TIA enrolled in the POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial who were treated with DAPT. We calculated Kaplan-Meier estimates of ischemic stroke risk at 2, 7, and 90 days. Risk estimates were further stratified according to ABCD

resultsA total of 1052 POINT participants experienced a TIA and were treated with DAPT. Cumulative ischemic stroke risks were 1.3% (95% CI, 0.6-1.9) at 2 days, 2.0% (95% CI, 1.2-2.9) at 7 days, and 4.1% (95% CI, 2.8-5.3) at 90 days, all below ABCD

conclusionsHigh-risk patients with TIA treated with DAPT had substantially lower early stroke risk than predicted by ABCD REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT00991029.

Indexed as

Dual Anti-Platelet TherapyIschemic Attack, TransientIschemic StrokePlatelet Aggregation InhibitorsStrokeAgedAspirinFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeAspirinPlatelet Aggregation InhibitorsaspirinclopidogrelDAPTminor strokeTIA

Identifiers

PMID41717934
PMCPMC13055761

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.